8-KEarnings & ResultsMaterial AgreementsOther Events+1

BRISTOL MYERS SQUIBB CO 8-K Report, Material Agreement (Sep 5, 2006)

Filed September 5, 2006For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) filed an 8-K report detailing a significant legal development concerning its blockbuster drug PLAVIX®. On August 31, 2006, a U.S. District Court granted a preliminary injunction against Apotex Inc. and Apotex Corp., halting the sale of their generic version of clopidogrel bisulfate, a drug that competes directly with PLAVIX®. This injunction, however, required the plaintiffs, including BMY's partnership, to post a substantial bond totaling $400 million. BMY arranged for a $200 million surety bond through Travelers Casualty and Surety Company of America, backed by significant collateral and indemnification agreements. This filing also includes a press release announcing a reduction in BMY's full-year 2006 earnings per share guidance, indicating potential headwinds or adjustments to financial expectations.

Key Highlights

  • 1Preliminary injunction granted against Apotex, halting sales of a generic competitor to PLAVIX®.
  • 2BMY's partnership and Sanofi are required to post a combined $400 million bond to secure the injunction.
  • 3BMY arranged a $200 million surety bond with Travelers Casualty and Surety Company of America.
  • 4BMY provided $200 million in cash collateral and extensive indemnification to the surety provider.
  • 5Sanofi also posted $200 million in security, with liability for the injunction shared 50-50 between BMY and Sanofi.
  • 6The company lowered its full-year 2006 earnings per share guidance.

Frequently Asked Questions

The preliminary injunction is significant because it temporarily prevents Apotex from selling a generic version of clopidogrel bisulfate, which directly competes with Bristol-Myers Squibb's highly profitable drug, PLAVIX®. This action aims to protect BMY's market share and revenue from PLAVIX® while patent litigation is ongoing.

The court required the plaintiffs (including BMY's partnership) to post a substantial bond as security for the defendant (Apotex) in case the injunction is later found to have been wrongly imposed. If the court eventually rules in favor of Apotex regarding the patent dispute, the bond amount would compensate Apotex for damages incurred due to the halted sales.

Lowering the full-year 2006 earnings per share (EPS) guidance suggests that the company anticipates lower profitability than previously projected. This could be due to various factors, including increased competition, R&D expenses, or operational challenges, and is a key metric investors watch for future performance expectations.

Bristol-Myers Squibb and its partner Sanofi have agreed to share any liabilities, costs, and damages related to the preliminary injunction and the posting of collateral on a 50-50 basis, as per their existing arrangements.